Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Christine Chen, Donna E. Reece, David Siegel, Ruben Niesvizky, Ralph V. Boccia, Edward A. Stadtmauer, Rafat Abonour, Paul Richardson, Jeffrey Matous, Shaji Kumar, Nizar J. Bahlis, Melissa Alsina, Robert Vescio, Steven E. Coutre, Dennis Pietronigro, Robert D. Knight, Jerome B. Zeldis, Vincent Rajkumar

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Abstract

Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006. In April 2005, the FDA and patient advocacy groups requested an expanded access programme to both provide lenalidomide to patients likely to benefit and obtain additional safety information. Relapsed/refractory MM patients received lenalidomide 25 mg/d (days 1-21) and dexamethasone 40 mg/d (days 1-4, 9-12, and 17-20 of cycles 1-4; days 1-4 only from cycle 5 onwards), in 4-week cycles until disease progression, study drug discontinuation, or lenalidomide approval. Of the 1438 patients enrolled, ∼60% were male, median age was 64 years, and 61·7% had Durie-Salmon stage III disease. Median time on study was 15·4 weeks (range: 0·1-49·1) and median dose was 25 mg. The most common adverse events (AEs) were haematological (49%), gastrointestinal (59%), and fatigue (55%). The most common grade ≥3 AEs were haematological (45%), fatigue (10%), and pneumonia (7%). The most common serious AEs were pneumonia (8%), pyrexia (4%), and deep-vein thrombosis (3%). Primary cause of death was disease progression (10%). Safety data confirmed known AEs of lenalidomide plus dexamethasone therapy in patients with relapsed/refractory MM.

Original languageEnglish (US)
Pages (from-to)164-170
Number of pages7
JournalBritish journal of haematology
Volume146
Issue number2
DOIs
StatePublished - Jul 2009

Keywords

  • Combination therapy
  • Lenalidomide plus dexamethasone
  • Multiple myeloma
  • Relapsed/refractory

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this